2024 World Conference on Lung Cancer (WCLC) - Posters-P4.07G.03 Real-World Clinical Outcomes and the Association Between EFS and OS in Early-Stage NSCLC Treated with Primary SBRT

P4.07G.03 Real-World Clinical Outcomes and the Association Between EFS and OS in Early-Stage NSCLC Treated with Primary SBRT

Back to course

Pdf Summary

This study evaluates the real-world clinical and economic outcomes of stage I-II (N0) non-small-cell lung cancer (NSCLC) patients treated with stereotactic body radiotherapy (SBRT) in the United States. Utilizing the SEER-Medicare database from 2007 to 2020, the analysis focused on patients who received primary SBRT, assessing event-free survival (rwEFS), overall survival (OS), healthcare resource utilization (HRU), and healthcare costs.<br /><br />Key findings showed that over 50% of these patients experienced disease recurrence within three years of SBRT initiation, with the median OS being 48.9 months. Recurrence was associated with significant clinical and economic burdens; these patients had more than double the risk of death compared to those without recurrence and faced significantly higher HRU and medical costs. The study found a moderate positive correlation between rwEFS and OS, reinforcing rwEFS as a valuable predictor for OS in this setting.<br /><br />The study underscores the potential of integrating immunotherapy with SBRT to enhance patient outcomes, particularly for those ineligible for surgery. It also highlights the considerable recurrence-associated healthcare resource implications, urging for strategies that delay recurrence and reduce associated costs.<br /><br />Limitations include potential misclassifications due to the nature of administrative claims data and results being mostly applicable to older, Medicare-insured populations. Despite these limitations, the study provides crucial insights into the burden of NSCLC recurrence and suggests areas for potential therapeutic advancements.

Asset Subtitle

Megan Daly

Meta Tag

Speaker Megan Daly

Topic Early-Stage NSCLC

Keywords

NSCLC

stereotactic body radiotherapy

SEER-Medicare database

real-world outcomes

event-free survival

overall survival

healthcare costs

disease recurrence

immunotherapy

healthcare resource utilization